Technology ID
TAB-3600
Novel ALDH1A1 (aldehyde dehydrogenase 1 family member A1) Inhibitors for the Treatment of Cancer
E-Numbers
E-214-2014-0
Lead Inventor
Vasiliou, Vasilis (University of Colorado Denver)
Co-Inventors
Simeonov, Anton (NCATS)
Jadhav, Ajit (NCATS)
Yang, Shyh-Ming
Maloney, David (NCATS)
Yasgar, Adam (NCATS)
Lal, Madhu (NCATS)
Chen, Ying (University of Colorado Denver)
Miller, Bettina (University of Colorado Denver)
Messersmith, Wells (University of Colorado Denver)
Arcaroli, John (University of Colorado Denver)
Jimeno, Antonio (The Regents of the University of Colorado, A Body Corporate)
Thompson, David (The Regents of the University of Colorado, A Body Corporate)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Oncology
Lead IC
NCATS
ICs
NCATS
This technology includes the identification and use of novel inhibitors of ALDH1A1 (aldehyde dehydrogenase 1 family member A1) for the treatment of multiple diseases, including cancer, inflammation, and obesity. ALDH1A1 is an enzyme that has a role in alcohol metabolism, and has been implicated in maintaining cancer stem cells. A high-throughput screen was conducted that identified novel ALDH1A1 inhibitors. Medicinal chemistry optimization led to the identification of two chemical series with high potency, selectivity, and favorable ADME (absorption, distribution, metabolism, and excretion) properties.
Commercial Applications
Further clinical work with the novel inhibitors could support the indication of these novel ALDH1A1 inhibitors for a variety of indications including but not limited to cancer, inflammation, and obesity.
Competitive Advantages
The compounds of this series represent the most potent, selective, and drug-like inhibitors of ALDH1A 1 described to date.
Licensing Contact: